Vidac Pharma Holding PLC

Vidac Pharma’s Canadian Notice of Allowance expands its oncology IP, boosting protection, partnership power, and market entry prospects while highlighting early‑stage risks.

Vidac Pharma’s recent executive share sales—disclosed under MAR—show no sharp price drop yet hint at future capital moves, highlighting stable governance and potential growth plans.

Vidac Pharma Holding PLC is poised for high‑leverage growth as it targets metabolic vulnerabilities in oncology, offering a unique upside in a shifting market.

Vidac Pharma: Investor insights on its €0.78 share price, Phase‑2 VDA‑1102 ointment, pediatric brain‑tumor compassionate use, and future oncology pipeline.

Vidac Pharma’s VDA‑1102 compassionate‑use case at the Eilat Paediatric Cancer Symposium shows real‑world success for a rare ependymoma, highlighting the company’s rapid‑translation potential in metabolic and dermatologic oncology.

Vidac Pharma’s first patient dose in Phase‑2b VDA‑1102 for high‑risk actinic keratosis marks a pivotal milestone, advancing a promising dermatologic therapy.